These sessions took place on 13th–17th September 2017, as part of the 26th European Academy of Dermatology and Venereology (EADV) Congress, in Geneva, Switzerland
Chairperson: Lluis Puig1
Speakers: Andrew Blauvelt,2 Kim Papp3
Poster Lead Author: Kristian Reich,4 Bruce E. Strober,5 Kenneth B. Gordon6
1. Department of Dermatology, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
2. Oregon Medical Research Center, Portland, Oregon, USA
3. Probity Medical Research, Waterloo, Canada
4. SClderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany
5. University of Connecticut Health Center and Probity Medical Research, Farmington, Connecticut, USA
6. Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Disclosure: Prof Puig has received grants, research support, honoraria, or consultation fees from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Eli Lilly and Company, Merck-Serono, MSD, Novartis, Pfizer, Sandoz, and VBL; he has also participated in a company-sponsored speaker bureau for Janssen. Prof Blauvelt has served as a scientific advisor and/or clinical study investigator for AbbVie, Aclaris, Allergan, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Inc., Eli Lilly and Company, Genentech/Roche, GlaxoSmithKline, Janssen, Leo, Merck Sharp & Dome, Novartis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB Pharma, Valeant, and Vidac. He has also been a paid speaker for Eli Lilly and Company, Janssen, Regeneron, and Sanofi Genzyme. Prof Papp has received honoraria or fees for serving on advisory boards, as a speaker, as a consultant, grants as an investigator from AbbVie, Amgen, Astellas, Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermira, Eli Lilly and Company, Forward Pharma, Galderma, Genetech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genzyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant. Prof Dr Reich has served as a consultant and/or paid speaker for, and/or participated in clinical trials sponsored by, AbbVie, Amgen, Biogen Idec, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Lilly, Medac, Merck & Co Inc., Novartis, Pfizer, Vertex, and Takeda. Prof Strober has received honoraria or fees for serving on advisory boards and as a consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly and Company, Janssen-Ortho, Leo Pharma, Maruho, Merck, Novartis, Pfizer, Sanofi/Regeneron, Sun Pharma, and UCB. Prof Gordon has received research support or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Janssen, and Lilly, and has acted as a consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Janssen, Lilly, Novartis, and Pfizer.
Acknowledgements: Writing assistance was provided by Shaylin Shadanbaz, ApotheCom, London, UK.
Support: The publication of this article was funded by Janssen. The views and opinions expressed are those of the authors and not necessarily Janssen.
Citation: EMJ. 2017;2:43-51.
The oral session consisted of a talk on the 2-year efficacy and safety of guselkumab in the treatment of moderate-to-severe psoriasis from the Phase III VOYAGE 1 trial. This was followed by an oral session consisting of presentations regarding the clinical efficacy of tildrakizumab in patients with chronic plaque psoriasis over 2 years of treatment, presented from the two Phase III trials, reSURFACE 1 and 2. In the poster session, data were presented on the association between psoriasis and severity index measures, the distribution of improvement measures in psoriasis, and the efficacy of guselkumab in treatment-experienced patients, as well as its impact on the comorbidities of anxiety and depression.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
The post Developments in the Treatment and Management of Psoriasis appeared first on European Medical Journal.